Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares Bought by Moody Aldrich Partners LLC

Moody Aldrich Partners LLC boosted its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 80.0% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 100,340 shares of the company's stock after acquiring an additional 44,606 shares during the quarter. Moody Aldrich Partners LLC owned 0.21% of Amphastar Pharmaceuticals worth $4,870,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Silvercrest Asset Management Group LLC grew its position in shares of Amphastar Pharmaceuticals by 35.1% in the first quarter. Silvercrest Asset Management Group LLC now owns 112,428 shares of the company's stock valued at $4,937,000 after purchasing an additional 29,182 shares during the period. Allspring Global Investments Holdings LLC lifted its stake in Amphastar Pharmaceuticals by 61.9% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 64,564 shares of the company's stock valued at $2,835,000 after buying an additional 24,678 shares in the last quarter. Intech Investment Management LLC acquired a new stake in Amphastar Pharmaceuticals in the 2nd quarter worth about $426,000. Nordea Investment Management AB increased its stake in Amphastar Pharmaceuticals by 0.4% during the 1st quarter. Nordea Investment Management AB now owns 333,014 shares of the company's stock worth $14,802,000 after buying an additional 1,209 shares in the last quarter. Finally, Granite Investment Partners LLC raised its holdings in shares of Amphastar Pharmaceuticals by 12.7% during the second quarter. Granite Investment Partners LLC now owns 397,514 shares of the company's stock valued at $15,901,000 after acquiring an additional 44,744 shares during the last quarter. Hedge funds and other institutional investors own 65.09% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on AMPH shares. Piper Sandler lowered their price target on Amphastar Pharmaceuticals from $71.00 to $66.00 and set an "overweight" rating on the stock in a research note on Thursday, August 8th. StockNews.com upgraded Amphastar Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Friday, October 18th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Amphastar Pharmaceuticals in a report on Thursday, August 8th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $63.00.

Insider Activity

In related news, CFO William J. Peters sold 10,282 shares of the company's stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $44.23, for a total value of $454,772.86. Following the completion of the sale, the chief financial officer now owns 94,103 shares of the company's stock, valued at approximately $4,162,175.69. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In other Amphastar Pharmaceuticals news, Director Floyd F. Petersen sold 3,000 shares of Amphastar Pharmaceuticals stock in a transaction on Thursday, September 5th. The stock was sold at an average price of $46.47, for a total value of $139,410.00. Following the sale, the director now owns 75,409 shares in the company, valued at $3,504,256.23. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO William J. Peters sold 10,282 shares of the company's stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $44.23, for a total value of $454,772.86. Following the completion of the transaction, the chief financial officer now directly owns 94,103 shares in the company, valued at approximately $4,162,175.69. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 34,383 shares of company stock valued at $1,524,123. 27.10% of the stock is currently owned by insiders.

Amphastar Pharmaceuticals Price Performance

Shares of Amphastar Pharmaceuticals stock traded down $0.20 on Thursday, hitting $49.63. 442,390 shares of the company were exchanged, compared to its average volume of 396,305. The company has a quick ratio of 2.63, a current ratio of 3.52 and a debt-to-equity ratio of 0.82. The company has a 50-day moving average price of $47.79 and a 200 day moving average price of $43.41. The stock has a market capitalization of $2.43 billion, a price-to-earnings ratio of 17.17, a price-to-earnings-growth ratio of 0.88 and a beta of 0.83. Amphastar Pharmaceuticals, Inc. has a 1-year low of $36.56 and a 1-year high of $65.92.

Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report) last announced its quarterly earnings data on Wednesday, August 7th. The company reported $0.85 EPS for the quarter, topping analysts' consensus estimates of $0.75 by $0.10. The firm had revenue of $182.39 million for the quarter, compared to the consensus estimate of $171.29 million. Amphastar Pharmaceuticals had a return on equity of 29.79% and a net margin of 23.36%. As a group, sell-side analysts predict that Amphastar Pharmaceuticals, Inc. will post 3.71 earnings per share for the current fiscal year.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.